

**IN THE CLAIMS**

Please amend the claims as follows.

1-22. Canceled.

231. (currently amended) A method ~~for~~of activating a receptor, comprising bringing said receptor into contact with an amphiphilic drug-oligomer conjugate comprising a therapeutic compound conjugated to an oligomer, wherein the oligomer comprises a lipophilic moiety coupled with ~~to~~ a hydrophilic moiety.

242. (currently amended) The method of claim ~~181~~1, further characterized in that said conjugate exhibits activity ~~in the~~ without cleavage of the therapeutic compound from the oligomer.

253. (currently amended) The method of claim ~~181~~1, wherein the receptor is a G-protein coupled receptor.

264. (currently amended) The method of claim ~~181~~1, wherein the receptor is an ~~Opioid~~ opioid receptor.


275. (currently amended) The method of claim ~~181~~1, wherein the receptor is ~~a Opioid~~ an opioid receptor; selected from the group consisting of  $\delta$ ,  $\mu$ , and  $\kappa$ .

286. (currently amended) The method of claim ~~181~~1, wherein the hydrophilic moiety is selected from the group consisting of sugar and PEG<sub>1-7</sub>.

297. (currently amended) The method of claim ~~181~~1, wherein the hydrophilic moiety is


selected from the group consisting of fatty acid, alkyl 1-26, cholesterol and adamantane.

308. (currently amended) The method of claim ~~181~~, wherein the therapeutic compound is a peptide having an added N-terminal residue selected from the group consisting of proline, and alanine.
319. (currently amended) The method of claim ~~181~~, wherein the therapeutic compound is a peptide or protein.
3210. (currently amended) The method of claim ~~181~~, wherein the therapeutic compound is a peptide and the peptide is selected from the group consisting of: enkephalin, adrenocorticotrophic hormone, adenosine deaminase, ribonuclease, alkaline phosphatase, angiotensin, antibodies, arginase, arginine deaminase, asparaginase, caerulein, calcitonin, chemotrypsin, cholecystokinin, clotting factors, dynorphins, ~~endorphins~~, endorphins, enkephalins, ~~enkephalins~~, erythropoietin, gastrin-releasing peptide, glucagon, hemoglobin, hypothalamic releasing factors, interferon, katacalcin, motilin, neuropeptide Y, neurotensin, non-naturally occurring opioids, ~~oxytocin~~ oxytocin, papain, parathyroid hormone, ~~peptides~~ prolactin, soluble CD-4, somatomedin, somatostatin, ~~somatostatin~~, somatotropin, superoxide dismutase, thyroid stimulating hormone, tissue plasminogen activator, trypsin, vasopressin, and analogues and active fragments of such peptides.
3311. (currently amended) The method of claim ~~181~~, wherein the amphiphilic oligomer is selected from the group consisting of:



(Formula 1);

wherein n=3 to 25 and m=1 to 6;



wherein  $n=3$  to 25 and  $m=1$  to 7;




wherein  $n=3$  to 25,  $m=1$  to 7 and  $X=\text{O}$  or  $\text{N}$ ;




wherein  $m=0$  to 5 and  $\text{R}=\text{cholesterol}$  or  $\text{adamantane}$ ; ~~or~~



wherein  $m=0$  to 5;



wherein  $m=0$  to 7; and



wherein  $m=1$  to 7 and  $X=\text{N}$  or  $\text{O}$ .

3412. (currently amended) The method of claim ~~181~~13, wherein the hydrophilic moiety is coupled to the hydrophobic moiety by a hydrolyzable bond.

3513. (currently amended) The method of claim ~~181~~13, wherein the hydrophilic moiety is

coupled to the hydrophobic moiety by a non-hydrolyzable bond.

36-63. Canceled.

~~64~~14. (new and currently amended) The method of claim 1, wherein the therapeutic compound is an opioid receptor agonist, antagonist or partial agonist/partial antagonist.

~~65~~15. (new and currently amended) The method of claim 1, wherein the therapeutic compound is an enkephalin.